MedTrace Logo

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

NCT07293923 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-27

No results posted yet for this study

Summary

The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left ventricular failure.

Conditions

  • Cardiogenic Shock
  • Heart Failure
  • Acute Myocardial Infarction (AMI)

Interventions

DEVICE

Elevate™ System

The Elevate™ percutaneous Left Ventricular Assist Device System

Sponsors & Collaborators

  • Magenta Medical Ltd.

    lead INDUSTRY

Principal Investigators

  • Yelena Lalazar · Magenta Medical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-05
Primary Completion
2026-05-30
Completion
2026-10-30

Countries

  • Georgia
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07293923 on ClinicalTrials.gov